Plus 8.0%, plus 0.8%, minus 1.3%. Those three numbers capture the uneven shape of Reckitt's (LSE:RKT) third quarter. Emerging Markets revenue rose 8.0% on a like-for-like basis to £1.17bn, Europe grew 0.8% to £867m, and North America fell 1.3% to £649m. Together the three …
Investor events are usually planned long in advance, and their importance can shift with circumstances. Reckitt's (LSE:RKT) North America event, scheduled for Thursday 19 November 2026 at its New Jersey headquarters, is a case in point. When the company published its third-quarter trading update …
Hikma's business model spans three main divisions: the US injectables business, which is the largest profit contributor and focuses on complex sterile generic injectables for hospital and acute care settings; the branded pharmaceuticals business, which sells branded medicines across MENA markets; and the generics …
CVS's business model is based on the acquisition and integration of independent veterinary practices into a professionally managed group, while retaining the clinical independence and local identity of individual practices. The company generates revenue from primary care consultations, diagnostic services, prescriptions, surgical procedures and …
Oxford Nanopore Technologies Plc (LSE:ONT) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: Investors are tracking sequencing-platform …
Eden Biosolutions PLC (LSE:EDEN) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: Recent company attention follows its …
Inspiration Healthcare Group PLC (LSE:IHC) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: Interim results have focused …
ImmuPharma plc (LSE:IMM) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: The clinical-stage biotechnology company is in …
IXICO Plc (LSE:IXI) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: The clinical-trial technology group is being …
SkinBioTherapeutics Plc (LSE:SBTX) attracts attention through its exposure to skin microbiome research and commercial skincare.